| Literature DB >> 28809935 |
Richard A Bryant1,2, Alison Schafer3, Katie S Dawson1,2, Dorothy Anjuri4, Caroline Mulili4, Lincoln Ndogoni5, Phiona Koyiet4, Marit Sijbrandij6, Jeannette Ulate7, Melissa Harper Shehadeh8, Dusan Hadzi-Pavlovic1, Mark van Ommeren8.
Abstract
BACKGROUND: Gender-based violence (GBV) represents a major cause of psychological morbidity worldwide, and particularly in low- and middle-income countries (LMICs). Although there are effective treatments for common mental disorders associated with GBV, they typically require lengthy treatment programs that may limit scaling up in LMICs. The aim of this study was to test the effectiveness of a new 5-session behavioural treatment called Problem Management Plus (PM+) that lay community workers can be taught to deliver. METHODS ANDEntities:
Mesh:
Year: 2017 PMID: 28809935 PMCID: PMC5557357 DOI: 10.1371/journal.pmed.1002371
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Flow diagram of progress through phases of a randomised trial comparing problem management plus versus enhanced usual care among women with a history of gender-based violence in urban Kenya.
EUC, enhanced usual care; PM+, Problem Management Plus.
Participant characteristics and trauma exposure assessed at baseline.
| Characteristic or exposure | PM+ ( | EUC ( | |
|---|---|---|---|
| 35.2 (14.1) | 35.9 (12.7) | 0.57 (0.57) | |
| 8.7 (3.6) | 8.2 (4.2) | 1.20 (0.23) | |
| 0.68 | |||
| Single | 25 (12.0) | 30 (14.1) | |
| Married | 122 (58.4) | 119 (56.1) | |
| Divorced/separated | 42 (20.1) | 45 (21.2) | |
| Widowed | 20 (9.5) | 18 (8.5) | |
| 104 (49.8) | 108 (50.9) | 0.12 | |
| 50 (23.9) | 35 (16.5) | 2.80 | |
| 7.0 (3.2) | 6.7 (3.3) | 0.75 (0.45) | |
| Disaster | 118 (56.5) | 102 (48.1) | |
| Fire | 123 (58.8) | 116 (54.7) | |
| Road accident | 121 (57.9) | 110 (51.9) | |
| Serious accident | 97 (46.4) | 105 (49.5) | |
| Chemical exposure | 70 (33.5) | 70 (33.0) | |
| Physical assault | 155 (74.2) | 153 (72.2) | |
| Assault with weapon | 104 (49.8) | 95 (44.8) | |
| Sexual assault | 59 (28.2) | 72 (34.0) | |
| Unwanted sexual contact | 59 (28.2) | 63 (29.7) | |
| War exposure | 59 (28.2) | 59 (27.8) | |
| Kidnapped | 43 (20.6) | 38 (17.9) | |
| Life-threatening illness | 109 (52.1) | 103 (48.6) | |
| Witness violent death | 103 (49.3) | 98 (46.2) | |
| Unexpected death of loved one | 159 (76.1) | 157 (74.1) | |
| Intimate partner violence | 153 (73.2) | 152 (71.7) | |
| GHQ-12 | 19.1 (6.0) | 18.8 (5.9) | 0.39 (0.69) |
| PCL | 33.7 (19.7) | 31.5 (18.9) | 1.2 (0.24) |
| WHODAS | 28.0 (7.5) | 27.2 (7.2) | 1.1 (0.26) |
| PSYCHLOPS | 16.6 (3.2) | 16.4 (3.3) | 0.67 (0.50) |
*Chi square test.
EUC, enhanced usual care; GHQ-12, 12-item General Health Questionnaire (range 0–36; higher scores indicate elevated anxiety or depression); LEC, Life Events Checklist; PCL, Posttraumatic Stress Disorder Checklist (range 0–80; higher scores indicate greater severity); PM+, Problem Management Plus; PSYCHLOPS, Personalized Outcome Profiles (range 0–20; higher scores indicate poorer outcome); WHODAS, WHO Disability Adjustment Scale (range 0–48; higher scores indicate more severe impairment).
Violence against women assessed at baseline.
| Event | PM+ ( | EUC ( | χ2 ( |
|---|---|---|---|
| Ever | 145 (69.4) | 150 (70.7) | 1.21 (0.27) |
| In past year | 80 (38.3) | 86 (40.6) | 0.49 (0.48) |
| Ever | 37 (17.7) | 43 (20.3) | 0.54 (0.46) |
| In past year | 17 (8.1) | 18 (8.5) | 1.05 (0.32) |
| Ever | 50 (23.9) | 57 (26.9) | 0.65 (0.42) |
| In past year | 26 (12.4) | 28 (13.2) | 0.09 (0.77) |
| Ever | 74 (35.4) | 59 (27.8) | 1.95 (0.16) |
| In past year | 46 (22.0) | 35 (16.5) | 0.23 (0.23) |
Data given as n (percent).
EUC, enhanced usual care; PM+, Problem Management Plus.
Estimated mean scores for primary and secondary outcome measures at baseline, posttreatment, and 3-month follow-up for women with a history of gender-based violence.
| Category | Outcome | PM+ ( | Enhanced usual care ( | Estimated mean difference from baseline | Effect size (95% CI) | |
|---|---|---|---|---|---|---|
| Baseline, mean (95% CI) | 19.4 (18.5–20.3) | 18.5 (17.6–19.4) | ||||
| Posttreatment, mean (95% CI) | 10.9 (9.9–12.0) | 13.9 (12.9–15.0) | 3.91 (2.40–5.42) | 0.001 | 0.67 (0.41 to 0.93) | |
| 3-month follow-up, mean (95% CI) | 8.7 (7.6–9.7) | 11.0 (10.0–12.1) | 3.33 (1.86–4.79) | 0.001 | 0.57 (0.32 to 0.83) | |
| Baseline, mean (95% CI) | 33.9 (30.9–36.9) | 31.5 (28.5–34.5) | ||||
| Posttreatment, mean (95% CI) | 9.7 (7.1–12.3) | 14.4 (11.8–17.0) | 7.13 (3.22–11.03) | 0.001 | 0.37 (0.17 to 1.03) | |
| 3-month follow-up, mean (95% CI) | 6.6 (4.4–8.8) | 8.2 (4.4–8.8) | 3.95 (0.06–7.83) | 0.05 | 0.26 (0.02 to 0.50) | |
| Baseline, mean (95% CI) | 28.1 (26.0–28.2) | 27.0 (25.9–28.1) | ||||
| Posttreatment, mean (95% CI) | 18.3 (17.1–19.5) | 20.5 (19.3–21.7) | 3.26 (1.49–5.03) | 0.001 | 0.44 (0.20 to 0.68) | |
| 3-month follow-up, mean (95% CI) | 16.3 (15.1–17.4) | 17.2 (16.1–18.2) | 1.96 (0.21–3.71) | 0.03 | 0.21 (0.00 to 0.41) | |
| Baseline, mean (95% CI) | 16.6 (16.0–17.2) | 16.5 (15.9–17.1) | ||||
| Posttreatment, mean (95% CI) | 9.5 (8.6–10.4) | 12.6 (11.7–13.5) | 3.20 (2.09–4.32) | 0.001 | 1.00 (0.65 to 1.35) | |
| 3-month follow-up, mean (95% CI) | 8.5 (7.6 to 9.5) | 10.6 (9.6–11.5) | 2.15 (0.98–3.32) | 0.001 | 0.67 (0.31 to 1.03) | |
| Baseline, mean (95% CI) | 8.9 (8.4–9.5) | 8.6 (8.1 to 9.2) | ||||
| 3-month follow-up, mean (95% CI) | 7.6 (7.0–8.3) | 7.0 (6.4–7.7) | 0.31 (0.02–1.23) | 0.51 | 0.03 (−0.23 to 0.15) | |
| Baseline, | 178/209 (85.2) | 182/212 (85.8) | 0.36 | 1.3 (0.7 to 2.2) | ||
| Posttreatment, | 60/168 (35.7) | 102/175 (58.3) | <0.001 | 2.5 (1.6 to 3.9) | ||
| 3-month follow-up, | 39/156 (25.0) | 59/163 (36.2) | <0.03 | 1.7 (1.0 to 2.8) | ||
| Baseline, | 153/209 (73.2) | 151/212 (71.2) | 0.89 | 1.03 (0.7 to 1.6) | ||
| Posttreatment, | 40/164 (24.4) | 51/172 (29.7) | 0.28 | 1.31 (0.8 to 2.1) | ||
| 3-month follow-up, | 28/155 (18.1) | 24/163 (14.7) | 0.41 | 0.78 (0.4 to 1.4) |
P values for continuous measures refer to between-group differences in change from baseline. P values for categorical measures refer to between-group differences at each assessment. Continuous outcomes are based on estimated mean values derived from HLM analyses. Categorical outcomes are based on treatment completers. Calculated mean differences differ marginally from absolute differences between estimated means because the estimated mean differences are derived from HLMs.
GHQ-12, 12-item General Health Questionnaire (range 0–36; higher scores indicate elevated anxiety or depression); HLM, hierarchical linear model; PCL, Posttraumatic Stress Disorder Checklist (range 0–80; higher scores indicate greater severity); PM+, Problem Management Plus; PSYCHLOPS, Personalized Outcome Profiles (range 0–20; higher scores indicate poorer outcome); PTSD, posttraumatic stress disorder; WHODAS, WHO Disability Adjustment Scale (range 0–48; higher scores indicate more severe impairment).
Fig 2Estimated means of primary and secondary outcomes.
Values based on estimated means derived from hierarchical linear model analyses. Error bars indicate 95% confidence intervals. EUC, enhanced usual care; GHQ, General Health Questionnaire; PCL, Posttraumatic Stress Disorder Checklist; PM+, Problem Management Plus; PSYCHLOPS, Personalized Outcome Profiles; WHODAS, WHO Disability Adjustment Scale.